Go Back

TATA 1MG TECHNOLOGIES PRIVATE LIMITED

Tata 1mg

U74140DL2015PTC279229

Get Comprehensive Report

₹1,999.00 ₹3,998.00
Suggest Edit Last updated: Jan 17, 2025
Key Metrics
  • No. of Employees3170
  • Founded Year 2015
  • Company StagePrivate Limited Company
  • Total Funding₹1,449.09 Cr
  • Industry

  • Headquarter
  • Company StatusAcquired
About Tata 1mg
Tata 1mg is India’s leading consumer health platform. It aspires to be the trusted health partner for all Indians and its mission is to make healthcare accessible, understandable and affordable for a billion Indians. It enables consumers to learn more about their medicines and also find more cost-effective substitutes. 1mg’s doctor platform aims to revolutionize how a consumer finds the right healthcare professional for his needs. It’s diagnostics service brings transparency and price-effectiveness to lab tests. 1mg is an initiative taken in the spirit of public service with a vision to empower Indian consumers and caregivers to select the most appropriate healthcare service at the best possible price
Business Model

Health tech startup 1Mg is an online platform that from where you can order all of your heath needs including allopathic, ayurvedic, homeopathic medicines, vitamins & nutrition supplements and other health-related products which will be delivered at home.

Top Competitors
PH
PharmeasyU74999MH2019PTC320220
PC
Pristyn CareU85300HR2018PTC075460
PR
PractoU72900KA2008PTC046374
NE
NetmedsU51505TN2010PLC077105
Tata 1mg Funding Details
Funding Highlights
Latest Funding RoundPrivate Equity
Total Funding Raised₹1,449.09 Cr
No. of Investments Made2
Total No. of Acquisitions6
Lead Investors4
Investors
  • Tata Digital, HBM Healthcare Investment, IFC, Mauritius Africa Fund
Funding Details
TheKredible's detailed funding report contains info about Funding raised by the company along with Lead Investors, Investors, Shareholding Strcuture, and its Investments & Acquisitions.
₹799.00 ₹1,598.00
Funding History
TheKredible's 'Funding History' report provides deep insights of Funding with list of Lead Investors
₹399.00 ₹798.00
Funding Per Year
A Funding report of the company's overall funding on yearly basis, segregated by the team TheKredible.
₹199.00 ₹398.00
Investment Company Done
Detailed report about the Invtestments made by the company till date.
₹499.00 ₹998.00
Acquisition Company Done
Detailed report about the Acquistions the company has done till date.
₹499.00 ₹998.00
Tata 1mg Financial Details
Financial Highlights
FY 2023-24 Revenue₹1,991.16 Cr
FY 2023-24 Expenses₹2,302.79 Cr
FY 2023-24 Profit/Loss-₹312.99 Cr
Net Cash Flow From Operations-₹270.68 Cr
Full Financial Details
Detailed report containing info about Business Model, year-wise Financial Comparison, Ratio Analysis and detailed Revenue and Expense breakdowns.
₹799.00 ₹1,598.00
Financial Comparison
A detailed report of year-wise Financial Comparison of the company
₹430.00 ₹860.00
Revenue Breakdown
A report and breakdown of the company's year-wise revenue streams.
₹399.00 ₹798.00
Expense Breakdown
A report and breakdown of the company's year-wise expenditures.
₹399.00 ₹798.00
Shareholding Structure
Team at TheKredible has gone through several ROC filings and portrayed Shareholding Structure of the company.
₹499.00 ₹998.00
Financial Ratio
Analysis of Financial Ratios which gives quick insights about the company's profitability and capital efficiency.
₹199.00 ₹398.00
Tata 1mg Key People
People Metrics
Current Core Team2
Board Members/Directors8

Core Team

PT
Prashant TandonCo-Founder
GA
Gaurav AgarwalCo-Founder

Board Members/Directors

PT
Prashant Tandon Director
MB
Mukesh BansalNominee Director
GK
Girish KrishnamurthyNominee Director
MH
Menon HariNominee Director
MJ
Matthew John KinsellaNominee Director
AV
Ankur VermaNominee Director
VC
Vanessa Cynthia FreyNominee Director
GA
Gaurav AggarwalDirector
Tata 1mg Documents

AY - 2018-19

Profit and Loss statement - Tata 1mg - 2018-19.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Tata 1mg for FY 2018-19.
₹249.00 ₹498.00
Balance Sheet - Tata 1mg - 2018-19.pdf
TheKredible's experts has summarized the Balance Sheet of Tata 1mg for FY 2018-19.
₹249.00 ₹498.00

AY - 2019-20

Profit and Loss statement - Tata 1mg - 2019-20.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Tata 1mg for FY 2019-20.
₹249.00 ₹498.00
Balance Sheet - Tata 1mg - 2019-20.pdf
TheKredible's experts has summarized the Balance Sheet of Tata 1mg for FY 2019-20.
₹249.00 ₹498.00

AY - 2020-21

Profit and Loss statement - Tata 1mg - 2020-21.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Tata 1mg for FY 2020-21.
₹249.00 ₹498.00
Balance Sheet - Tata 1mg - 2020-21.pdf
TheKredible's experts has summarized the Balance Sheet of Tata 1mg for FY 2020-21.
₹249.00 ₹498.00

AY - 2021-22

Profit and Loss statement - Tata 1mg - 2021-22.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Tata 1mg for FY 2021-22.
₹249.00 ₹498.00
Balance Sheet - Tata 1mg - 2021-22.pdf
TheKredible's experts has summarized the Balance Sheet of Tata 1mg for FY 2021-22.
₹249.00 ₹498.00

AY - 2022-23

Profit and Loss statement - Tata 1mg - 2022-23.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Tata 1mg for FY 2022-23.
₹249.00 ₹498.00
Balance Sheet - Tata 1mg - 2022-23.pdf
TheKredible's experts has summarized the Balance Sheet of Tata 1mg for FY 2022-23.
₹249.00 ₹498.00

AY - 2023-24

Profit and loss statement - Tata 1mg - 2023-24.pdf
TheKredible's experts has summarized the Profit and Loss Statement of Tata 1mg for FY 2023-24
₹249.00 ₹498.00
Balance sheet - Tata 1mg - 2023-24.pdf
TheKredible's experts has summarized the Balance Sheet of Tata 1mg for FY 2023-24
₹249.00 ₹498.00

Subscribe to our newsletter to stay updated

Weekly Funding Reports
Funding Report
Weekly Funding Report [21 Apr - 26 Apr, 2025]
Monthly Funding Reports
Funding Report
Indian startup funding declines over 50% in Februa...

Get your Customised Report

With an exclusive 20% off on your order

Latest Industry Reports
Industry Report
HealthTech’s Rebound: After a Downturn, HealthTech...